[go: up one dir, main page]

PE20081900A1 - Heterociclos como antagonistas de orexina - Google Patents

Heterociclos como antagonistas de orexina

Info

Publication number
PE20081900A1
PE20081900A1 PE2008000605A PE2008000605A PE20081900A1 PE 20081900 A1 PE20081900 A1 PE 20081900A1 PE 2008000605 A PE2008000605 A PE 2008000605A PE 2008000605 A PE2008000605 A PE 2008000605A PE 20081900 A1 PE20081900 A1 PE 20081900A1
Authority
PE
Peru
Prior art keywords
halogen
phenyl
methyl
optionally substituted
pyridin
Prior art date
Application number
PE2008000605A
Other languages
English (en)
Inventor
Luca Gobbi
Henner Knust
Parichehr Malherbe
Matthias Nettekoven
Emmanuel Pinnard
Olivier Roche
Mark Rogers-Evans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081900(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081900A1 publication Critical patent/PE20081900A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H O ALQUILO INFERIOR(C1-C7); R3 ES H, HALOGENO, ALQUILO INFERIOR(C1-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO O ALCOXI INFERIOR(C1-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO; R4 ES HALOGENO, ALQUILO INFERIOR(C1-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO O ALCOXI INFERIOR(C1-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO; HETARILO ES UN ANILLO HETEROAROMATICO QUE ES UN COMPUESTO DE FORMULA (i), (ii), (iii) O (iv). SON COMPUESTOS PREFERIDOS: N-METIL-2-{2-METIL-4-[2-(4-TRIFLUORMETIL-FENIL)-ETIL]-6,7-DIHIDRO-4H-TIENO[3,2-c]PIRIDIN-5-IL}-2-FENIL-ACETAMIDA, 2-{4-[2-(4-METOXI-FENIL)-ETIL]-2-METIL-6,7-DIHIDRO-4H-TIENO[3,2-c]PIRIDIN-5-IL}-N-METIL-2-FENIL-ACETAMIDA, 2-{4-[2-(4-METOXI-FENIL)-ETIL]-2,3-DIMETIL-6,7-DIHIDRO-4H-TIENO[3,2-c]PIRIDIN-5-IL}-N-METIL-2-FENIL-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA OREXINA SIENDO UTILES EN EL TRATAMIENTO DE INSOMNIO, ANSIEDAD, DEPRESION, ANSIEDAD, ESQUIZOFRENIA
PE2008000605A 2007-04-04 2008-04-03 Heterociclos como antagonistas de orexina PE20081900A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07105596 2007-04-04

Publications (1)

Publication Number Publication Date
PE20081900A1 true PE20081900A1 (es) 2009-01-26

Family

ID=39469467

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000605A PE20081900A1 (es) 2007-04-04 2008-04-03 Heterociclos como antagonistas de orexina

Country Status (16)

Country Link
US (1) US8067598B2 (es)
EP (1) EP2144906B1 (es)
JP (1) JP2010523518A (es)
KR (1) KR101158976B1 (es)
CN (1) CN101646668A (es)
AR (1) AR065904A1 (es)
AT (1) ATE512963T1 (es)
AU (1) AU2008235528B2 (es)
CA (1) CA2681163A1 (es)
CL (1) CL2008000957A1 (es)
ES (1) ES2365444T3 (es)
IL (1) IL200781A0 (es)
MX (1) MX2009010727A (es)
PE (1) PE20081900A1 (es)
TW (1) TW200845973A (es)
WO (1) WO2008122513A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US20120101106A1 (en) * 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
WO2011061318A1 (en) 2009-11-23 2011-05-26 N.V. Organon Heterocylic compounds as antagonists of the orexin receptors
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
KR20140124398A (ko) 2012-02-07 2014-10-24 이올라스 테라퓨틱스, 인코포레이티드 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
CN109219606B (zh) 2016-02-12 2021-10-01 阿斯利康(瑞典)有限公司 食欲素受体调节剂的卤素取代的哌啶

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703392B2 (en) * 2000-03-14 2004-03-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
JP3876872B2 (ja) * 2002-10-15 2007-02-07 ソニーケミカル＆インフォメーションデバイス株式会社 エレクトロルミネスセンスポリマー、ビスフルオレニルシラン化合物及び有機ｅｌ素子
BRPI0408681A (pt) 2003-03-26 2006-03-28 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
MX2008011647A (es) * 2006-03-15 2008-09-22 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolina para mejorar la funcion de la memoria.
EP2013209B1 (en) * 2006-04-26 2011-01-19 Actelion Pharmaceuticals Ltd. Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists

Also Published As

Publication number Publication date
ES2365444T3 (es) 2011-10-05
CN101646668A (zh) 2010-02-10
US20080249125A1 (en) 2008-10-09
JP2010523518A (ja) 2010-07-15
AU2008235528A1 (en) 2008-10-16
AU2008235528B2 (en) 2012-11-08
US8067598B2 (en) 2011-11-29
MX2009010727A (es) 2009-10-26
WO2008122513A1 (en) 2008-10-16
IL200781A0 (en) 2010-05-17
EP2144906B1 (en) 2011-06-15
EP2144906A1 (en) 2010-01-20
KR101158976B1 (ko) 2012-06-21
CL2008000957A1 (es) 2008-10-10
AR065904A1 (es) 2009-07-08
KR20090127313A (ko) 2009-12-10
ATE512963T1 (de) 2011-07-15
TW200845973A (en) 2008-12-01
CA2681163A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
PE20081900A1 (es) Heterociclos como antagonistas de orexina
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20081612A1 (es) Analogos de las pterinas
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
SV2010003642A (es) Compuestos
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20130184A1 (es) Compuesto heterociclico
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20081851A1 (es) Derivados de espiropiperidina-glicinamida
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20110410A1 (es) Derivado de 7-piperidinoalquil-3,4-dihidroquinolona
PE20160839A1 (es) Derivados de 4-azaindol
ES2148227T3 (es) Derivados de 1-piperazino-1,2-dihidroindeno.
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal